Phase III Biologics Company Looking to Raise Capital for Plasma-derived Therapeutics
Phase III plasma-derived therapeutic company is ready to build the commercial facility with One Million Liter annual capacity, in Dallas Texas
With $1.5 Billion in future annual revenue.
We are looking for $60-240 Million depending on the investment levels.
+ Private-Equity owned, Phase III plasma-derived therapeutic company
is ready to build the commercial facility with One Million Liter annual
capacity, in Dallas Texas, with $1.5 Billion in future annual revenue.
+ C-Suite Leadership Team each with 25 years of industry experience in
Hemophilia, Blood Plasma and Biologic Therapeutics, leading a team of
30 scientists over the last 10 years.
+ This Biologics Company is focused on the development,
manufacturing and commercialization of life-saving, plasma-derived
therapeutics using high yield proprietary technology.
+ Successful completion of Adult and Pediatric Phase III Intravenous
Immunoglobulin (IVIG) Clinical Trial in Primary Immune Deficiency
Disease (PIDD). FDA confirmation, no clinical trial needed for second
commercial product Albumin.
+ $12 Billion US market opportunity, consistent high-volume growth,
underserved market for protein IVIG.
+ 80% of first year production capacity pre-sold prior to construction
of commercial facility.
+ 70% of raw material blood plasma supply chain for first 3 years of
operation is already secured.
+ Please request the CIM after Fully Executed NDA.